Perfil de autoanticuerpos y asociación con patrones inmuno-electroforéticos en pacientes con esclerosis sistémica
DOI:
https://doi.org/10.29166/ciencias_medicas.v42i1.1571Keywords:
systemic sclerosis, autoantibodies, patterns, immunoelectrophoresisAbstract
Introduction: Scleroderma is an autoimmune disease, systemic and mediated by genetic and environmental factors. One of its markers is the presence of autoantibodies with clinical value, diagnosis and prognosis.
Subjects and methods: a descriptive, observational and relational study carried out in patients diagnosed with systemic sclerosis who were treated at the Rheumatology Unit of the Hospital Carlos Andrade Marín from June 2014 to May 2015. The data were processed by correspondence analysis and Chi square calculation in the package Statistic SPSS 22 version.
Results: anti-topoisomerase antibodies were detected in 18 individuals (22.5%), anti-centromere (n=38, 47.5%), antinuclear antibodies (n=13, 16.3%), anti-ribonucleoprotein (n = 7, 8.8%) and without antibodies in 4 individuals (5%). As regards immune-electrophoretic patterns, the centromeric pattern was determined in 23 subjects (28.8%), fine and thick mottled (n = 17, 21.3% each), homogeneous (n = 8, 10%), nucleolar = 7, 8.8%) and cytoplasmic (n = 1, 1.3%); 7 patients (8.8%) were negative. The chi-square test yielded a value of 116.3 of the autoantibodies-immunofluorescence ratio, with a value of p=0.0000. Correspondence analysis showed the following associations: a) antinuclear antibodies and nucleolar pattern (p= 0.0021), antinuclear antibodies and thick speckle pattern (p=0.0123), anticentromere antibodies and centromeric pattern (p=0.0000) (p=0.0031), anti-topoisomerase I antibodies and homogeneous pattern (p=0.0001) and anti-ribonucleoprotein antibodies and thick speckle pattern (p=0.0000).
Conclusion: The profile of autoantibodies in patients with systemic sclerosis has a similar distribution to global publications, and is statistically significant with his immune-electrophoretic patterns.
Downloads
Metrics
References
Chung L, Utz P. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Current Rheumatology Reports 2004; 6:156–163.
Behmanesh F, et al. Autoantibody profile in systemic sclerosis. Acta Medica Iranica 2010; 48(1):12-20.
Kayser C, Fritzler M. Autoantibodies in systemic sclerosis: unanswered questions. Frontiers in immunology 2015; 6:1-6.
Walker J, Fritzler M. Update on autoantibodies in systemic sclerosis. Current Opinion in Rheumatology 2007; 19:580–591.
Schneeberger D, et al. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology 2013; 52:560-567.
Ho K, Reveille J. Review. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93.
Wielosz E, Dryglewska M, Majdan M. Serological profile of patients with systemic sclerosis. Postepy Hig Med Dosw 2014; 68:987-991.
Tormey V, et al. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001; 40:1157-1162.
Hirakata M, et al. Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest 1993; 91:2665-2672.
Kelly A, Derk C. Anti-RNA polymerase III antibodies in systemic sclerosis. Open Journal of Rheumatology and Autoimmune Diseases 2015; 5:81-86.
Wusirika R, et al. The assessment of anti–endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003; 120:596-606.
Fineschi S, et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis & Rheumatism 2008; 58(12):3913–3923.
Wolf S, et al. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endotelial pro-inflammatorycascades. Vascular Pharmacology 2013; 59:19–26.
Svegliati S, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
Cabiedes J, Nuñez C. Anticuerpos antinucleares. Reumatol Clin 2010; 6(4):224–230.
Soto M, et al. Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria:Analytical study in a specialized health institute, one year follow-up. Results in Immunology 2015; 5:13–22.
Adams B, Mutasim D. Importancia diagnóstica de la determinación de los anticuerpos antinucleares.International Journal of Dermatology 2000; 39:887-891.
Benítez C, et al. Concordancia entre determinación de anticuerpos por inmunofluorescencia e inmunoensayo lineal. Medicina & Laboratorio 2011; 17(9-10):429-43.
Rehman H. Antinuclear antibodies: when to test and how to interpret findings. Order ANA assays only when clinical features suggest a connective tissue disorder. Let ANA immunofluorescent patterns direct additional testing decisions. The Journal of Family Practice 2015; 64(1):E5-E8.
Valentini G, et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care & Research 2014; 66(10):1520–1527.
